Thioredoxin-1 confines T cell alloresponse and pathogenicity in graft-versus-host disease

Oxidative stress is elevated in the recipients of allogeneic hematopoietic transplantation (allo-HCT) and likely contributes to the development of graft-versus-host disease (GVHD). GVHD is characterized by activation, expansion, cytokine production and migration of alloreactive donor T cells, and re...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of clinical investigation Vol. 129; no. 7; pp. 2760 - 2774
Main Authors Sofi, M Hanief, Wu, Yongxia, Schutt, Steven D, Dai, Min, Daenthanasanmak, Anusara, Heinrichs Voss, Jessica, Nguyen, Hung, Bastian, David, Iamsawat, Supinya, Selvam, Shanmugam Panneer, Liu, Chen, Maulik, Nilanjana, Ogretmen, Besim, Jin, Junfei, Mehrotra, Shikhar, Yu, Xue-Zhong
Format Journal Article
LanguageEnglish
Published United States American Society for Clinical Investigation 01.07.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Oxidative stress is elevated in the recipients of allogeneic hematopoietic transplantation (allo-HCT) and likely contributes to the development of graft-versus-host disease (GVHD). GVHD is characterized by activation, expansion, cytokine production and migration of alloreactive donor T cells, and remains a major cause of morbidity and mortality after allo-HCT. Hence, strategies to limit oxidative stress in GVHD are highly desirable. Thioredoxin1 (Trx1) counteracts oxidative stress by scavenging reactive oxygen species (ROS) and regulating other enzymes that metabolize H2O2. The present study sought to elucidate the role of Trx1 in the pathophysiology of GVHD. Using murine and xenograft models of allogeneic bone marrow transplantation (allo-BMT) and genetic (human Trx1-transgenic, Trx1-Tg) as well as pharmacologic (human recombinant Trx1, RTrx1) strategies; we found that Trx1-Tg donor T cells or administration of the recipients with RTrx1 significantly reduced GVHD severity. Mechanistically, we observed RTrx1 reduced ROS accumulation and cytokine production of mouse and human T cells in response to alloantigen stimulation in vitro. In allo-BMT settings, we found that Trx1-Tg or RTrx1 decreased downstream signaling molecules including NFκB activation and T-bet expression, and reduced proliferation, IFN-γ production and ROS accumulation in donor T cells within GVHD target organs. More importantly, administration of RTrx1 did not impair the graft-versus-leukemia (GVL) effect. Taken together, the current work provides a strong rationale and demonstrates feasibility to target the ROS pathway, which can be readily translated into clinic.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0021-9738
1558-8238
DOI:10.1172/JCI122899